16:26 EDT Hims & Hers shares drop over 10% after reporting Q2 results
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- HIMS Upcoming Earnings Report: What to Expect?
- Truist says FDA GLP-1 adverse events report ‘likely a non-event’ for Hims & Hers
- FDA warns of possible overdoses with compounded semaglutide injections
- Hims & Hers lower after FDA warns of dosing errors with Ozempic
- Hims and Hers Health call volume above normal and directionally bullish